Sphingolipid Degradation in Leishmania (Leishmania) amazonensis

PLoS Neglected Tropical Diseases

Volumn 6, Issue 12, 2012, Pages

  Pillai, Agiesh Balakrishna ^a   Xu, Wei ^a   Zhang, Ou ^a   Zhang, Kai ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INOSITOL PHOSPHOSPHINGOLIPID PHOSPHOLIPASE; INTERLEUKIN 10; INTERLEUKIN 4; PHOSPHOLIPASE; SPHINGOLIPID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DELETION; HYPERSENSITIVITY; IMMUNOFLUORESCENCE TEST; LEISHMANIA; LIPID DEGRADATION; MACROPHAGE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE VIRULENCE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SKIN LEISHMANIASIS; SURVIVAL; WESTERN BLOTTING;

ANIMALS; DISEASE MODELS, ANIMAL; DNA, PROTOZOAN; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENETIC COMPLEMENTATION TEST; HUMANS; LEISHMANIA MEXICANA; LEISHMANIASIS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA; SPHINGOLIPIDS; SURVIVAL ANALYSIS; TYPE C PHOSPHOLIPASES; VIRULENCE FACTORS;

EID: 84872046836     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001944     Document Type: Article

References (48)

1. Cunningham AC, (2002) Parasitic adaptive mechanisms in infection by Leishmania. Exp Mol Pathol 72: 132-141.
2. Myler PJ, (2008) Searching the Tritryp genomes for drug targets. Adv Exp Med Biol 625: 133-140.
3. Banuls AL, Hide M, Prugnolle F, (2007) Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol 64: 1-109.
4. Berman J, (2003) Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 16: 397-401.
5. Castillo E, Dea-Ayuela MA, Bolas-Fernandez F, Rangel M, Gonzalez-Rosende ME, (2010) The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives. Curr Med Chem 17: 4027-4051.
6. Bates PA, Rogers ME, (2004) New insights into the developmental biology and transmission mechanisms of Leishmania. Curr Mol Med 4: 601-609.
7. Chelbi I, Kaabi B, Bejaoui M, Derbali M, Zhioua E, (2009) Spatial correlation between Phlebotomus papatasi Scopoli (Diptera: Psychodidae) and incidence of zoonotic cutaneous leishmaniasis in Tunisia. J Med Entomol 46: 400-402.
8. Zhang O, Wilson MC, Xu W, Hsu FF, Turk J, et al. (2009) Degradation of host sphingomyelin is essential for Leishmania virulence. PLoS Pathog 5 (12):: e1000692 PMCID: 2784226.
9. Xu W, Xin L, Soong L, Zhang K, (2011) Sphingolipid degradation by Leishmania is required for its resistance to acidic pH in the mammalian host. Infection and Immunity 79 (8):: 3377-3387 PMCID: 3147570.
10. Zhang O, Xu W, Pillai A, Zhang K, (2012) Developmentally Regulated Sphingolipid Degradation in Leishmania major. PLoS One 7 (2):: e31059 PMCID: 3267774.
11. Lainson R, (1983) The American leishmaniases: some observations on their ecology and epidemiology. Trans R Soc Trop Med Hyg 77: 569-596.
12. Silveira FT, Lainson R, Corbett CE, (2004) Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 99: 239-251.
13. Colmenares M, Kar S, Goldsmith-Pestana K, McMahon-Pratt D, (2002) Mechanisms of pathogenesis: differences amongst Leishmania species. Trans R Soc Trop Med Hyg 96 Suppl 1: S3-7.
14. Convit J, Ulrich M, Fernandez CT, Tapia FJ, Caceres-Dittmar G, et al. (1993) The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 87: 444-448.
15. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C, (2004) Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 53: 158-166.
16. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, et al. (1993) Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 91: 1390-1395.
17. Sacks D, Noben-Trauth N, (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
18. Afonso LC, Scott P, (1993) Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun 61: 2952-2959.
19. McMahon-Pratt D, Alexander J, (2004) Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol Rev 201: 206-224.
20. Xin L, Li Y, Soong L, (2007) Role of interleukin-1beta in activating the CD11c(high) CD45RB- dendritic cell subset and priming Leishmania amazonensis-specific CD4+ T cells in vitro and in vivo. Infect Immun 75: 5018-5026.
21. Soong L, Chang CH, Sun J, Longley BJ Jr, Ruddle NH, et al. (1997) Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. J Immunol 158: 5374-5383.
22. Antoine JC, Prina E, Lang T, Courret N, (1998) The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Trends Microbiol 6: 392-401.
23. Wilson J, Huynh C, Kennedy KA, Ward DM, Kaplan J, et al. (2008) Control of parasitophorous vacuole expansion by LYST/Beige restricts the intracellular growth of Leishmania amazonensis. PLoS Pathog 4: e1000179.
24. Franca-Costa J, Wanderley JL, Deolindo P, Zarattini JB, Costa J, et al. (2012) Exposure of Phosphatidylserine on Leishmania amazonensis Isolates Is Associated with Diffuse Cutaneous Leishmaniasis and Parasite Infectivity. PLoS One 7: e36595.
25. Ha DS, Schwarz JK, Turco SJ, Beverley SM, (1996) Use of the green fluorescent protein as a marker in transfected Leishmania. Mol Biochem Parasitol 77: 57-64.
26. Kapler GM, Coburn CM, Beverley SM, (1990) Stable transfection of the human parasite Leishmania major delineates a 30-kilobase region sufficient for extrachromosomal replication and expression. Mol Cell Biol 10: 1084-1094.
27. Spath GF, Beverley SM, (2001) A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp Parasitol 99: 97-103.
28. Eperon S, McMahon-Pratt D, (1989) Extracellular cultivation and morphological characterization of amastigote-like forms of Leishmania panamensis and L. braziliensis. J Protozool 36: 502-510.
29. Hodgkinson VH, Soong L, Duboise SM, McMahon-Pratt D, (1996) Leishmania amazonensis: cultivation and characterization of axenic amastigote-like organisms. Exp Parasitol 83: 94-105.
30. Titus RG, Muller I, Kimsey P, Cerny A, Behin R, et al. (1991) Exacerbation of experimental murine cutaneous leishmaniasis with CD4+ Leishmania major-specific T cell lines or clones which secrete interferon-gamma and mediate parasite-specific delayed-type hypersensitivity. Eur J Immunol 21: 559-567.
31. Zhang K, Showalter M, Revollo J, Hsu FF, Turk J, et al. (2003) Sphingolipids are essential for differentiation but not growth in Leishmania. EMBO J 22: 6016-6026 PMCID: 275442.
32. Racoosin EL, Beverley SM, (1997) Leishmania major: promastigotes induce expression of a subset of chemokine genes in murine macrophages. Exp Parasitol 85: 283-295.
33. Ji J, Sun J, Qi H, Soong L, (2002) Analysis of T helper cell responses during infection with Leishmania amazonensis. Am J Trop Med Hyg 66: 338-345.
34. Titus RG, Marchand M, Boon T, Louis JA, (1985) A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 7: 545-555.
35. Vargas-Inchaustegui DA, Xin L, Soong L, (2008) Leishmania braziliensis infection induces dendritic cell activation, ISG15 transcription, and the generation of protective immune responses. J Immunol 180: 7537-7545.
36. Okamoto Y, Vaena de Avalos S, Hannun YA, (2003) Functional analysis of ISC1 by site-directed mutagenesis. Biochemistry 42: 7855-7862.
37. Gupta N, Goyal N, Rastogi AK, (2001) In vitro cultivation and characterization of axenic amastigotes of Leishmania. Trends Parasitol 17: 150-153.
38. Rymarchyk SL, Lowenstein H, Mayette J, Foster SR, Damby DE, et al. (2008) Widespread natural variation in murine natural killer T-cell number and function. Immunology 125: 331-343.
39. Karmakar S, Bhaumik SK, Paul J, De T, (2012) TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis. PLoS Pathog 8: e1002646.
40. Karmakar S, Paul J, De T, (2011) Leishmania donovani glycosphingolipid facilitates antigen presentation by inducing relocation of CD1d into lipid rafts in infected macrophages. Eur J Immunol 41: 1376-1387.
41. Guimaraes ET, Santos LA, Ribeiro dos Santos R, Teixeira MM, dos Santos WL, et al. (2006) Role of interleukin-4 and prostaglandin E2 in Leishmania amazonensis infection of BALB/c mice. Microbes Infect 8: 1219-1226.
42. Jones DE, Buxbaum LU, Scott P, (2000) IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J Immunol 165: 364-372.
43. Qi H, Ji J, Wanasen N, Soong L, (2004) Enhanced replication of Leishmania amazonensis amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis. Infect Immun 72: 988-995.
44. Wanasen N, MacLeod CL, Ellies LG, Soong L, (2007) L-arginine and cationic amino acid transporter 2B regulate growth and survival of Leishmania amazonensis amastigotes in macrophages. Infect Immun 75: 2802-2810.
45. Pinheiro RO, Nunes MP, Pinheiro CS, D'Avila H, Bozza PT, et al. (2009) Induction of autophagy correlates with increased parasite load of Leishmania amazonensis in BALB/c but not C57BL/6 macrophages. Microbes Infect 11: 181-190.
46. Lara ML, Layrisse Z, Scorza JV, Garcia E, Stoikow Z, et al. (1991) Immunogenetics of human American cutaneous leishmaniasis. Study of HLA haplotypes in 24 families from Venezuela. Hum Immunol 30: 129-135.
47. Petzl-Erler ML, Belich MP, Queiroz-Telles F, (1991) Association of mucosal leishmaniasis with HLA. Hum Immunol 32: 254-260.
48. Blackwell JM, (1999) Tumour necrosis factor alpha and mucocutaneous leishmaniasis. Parasitol Today 15: 73-75.